This is the first Programming Document fully grounded in the EMCDDA Strategy 2025 and it sets a milestone in the strategic and operational planning framework of the EMCDDA. Among the highlights for this period will be a follow up on the outcome of the fourth external evaluation of the EMCDDA. An ongoing priority will be the implementation of the EU Early Warning System on new psychoactive substances (EU EWS).
This content was published in the Best pratice portal update briefing on 18.03.2019
The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EU drugs agency (EMCDDA). The project analysed wastewater in 73 European cities in 20 European countries in March 2018 to explore the drug-taking behaviours of their inhabitants. The 2018 study points to an increase in the detection of amphetamine, cocaine and MDMA in wastewater samples, compared to the 2017 figures.
This list of frequently asked questions (FAQ) answers some of the common questions on the background, use, application and interpretation of wastewater-based epidemiology.
The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in a range of European cities and towns to explore the drug-taking habits of those who live in them. The results provide a valuable snapshot of the drug flow through the cities involved, revealing marked geographical variations.
The EU drugs agency (EMCDDA) and Albania will cooperate more actively on monitoring the drug phenomenon in future, thanks to a Working Arrangement being concluded today in Vienna (1). The agreement is being signed by EMCDDA Director Alexis Goosdeel and by the Albanian Deputy Minister of the Interior Besfort Lamallari and Deputy Minister of Health and Social Protection Mira Rakacolli in the presence of Dimitris Avramopoulos, European Commissioner responsible for Migration, Home Affairs and Citizenship.
Ambassador Adam Namm, Executive Secretary of the Inter-American Drug Abuse Control Commission (CICAD) of the Organization of American States (OAS) visited the EMCDDA today to discuss with the agency’s Director Alexis Goosdeel perspectives for the next EMCDDA–CICAD work programme (2019–23).
This report considers substance use prevention in Europe through the lens of a system, highlighting the wide range of factors that need to be addressed to successfully implement substance use prevention programmes and policies. They are considered from different viewpoints by practitioners, policymakers and researchers. Systems thinking may have the potential to unify these differing perspectives within a single model.
Around 37 million women in Europe have used an illicit drug at least once in their lifetime. Some 100 000 enter drug treatment every year and nearly 2 000 die from drug overdose. Meanwhile, over the last decade, the gender gap has been narrowing among young school students who use drugs. Today, to commemorate International Women’s Day, the EMCDDA releases a new motion graphic exploring ‘Why gender matters in drug addiction’.
Today, EMCDDA Director Alexis Goosdeel welcomes to the agency Dr Andrea Ammon, Executive Director of the Stockholm-based European Centre for Disease Prevention and Control (ECDC).
This report presents a summary of the key findings from drug treatment facility surveys carried out in 2017 in Albania, Bosnia and Herzegovina, Serbia and the territory of Kosovo. The results provide insight into the characteristics and capacity of the treatment systems, as well as the availability and provision of treatment interventions. The report also considers the implications for practice and policy.
The EMCDDA has added 16 new programmes to Xchange, its online registry of evidence-based prevention programmes. Launched in October 2017, and now ending its pilot phase, the registry showcases interventions that European evaluation studies demonstrate to have promising outcomes relating to substance use. Five of the new programmes focus on substance use prevention and 11 on crime and delinquency prevention. At present, Xchange contains 38 programmes.
This year, the EMCDDA has launched a three-year project — EU4Monitoring Drugs (EU4MD) — which will intensify its cooperation with the countries of the European Neighbourhood Policy (ENP)(1)(2). The EU-funded project, running until the end of 2021, will support national and regional readiness in the ENP area to identify and respond to drug-related health and security threats.
EU-ANSA is the EU Agencies Network on Scientific Advice, one of the sub-networks operating under the tutelage of the Heads of EU agencies network. EU-ANSA allows dialogue between chief scientists or equivalent senior scientific staff from agencies with a strong science component to their work and which provide scientific and technical advice to the EU institutions, Member States and other relevant EU policymakers.
Two new working arrangements will be signed in Brussels today between the EMCDDA and the European Chemicals Agency (ECHA) and the European Food Safety Authority (EFSA).
The EMCDDA will now be cooperating with five EU agencies under new legislation applying from 23 November 2018, which strengthens the EU Early Warning System on new psychoactive substances (1). Three existing working arrangements with the European Centre for Disease Prevention and Control (ECDC); the European Medicines Agency (EMA) and Europol were updated and signed in December 2018 (2).
The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament.
The EMCDDA has been awarded a Gold Medal of the Order of Merit of the Spanish national plan on drugs (Delegación del Gobierno para el Plan Nacional sobre Drogas/DGPNSD) in recognition of, and appreciation for, its work over the past 20 years. EMCDDA Director Alexis Goosdeel is in Madrid today to receive the medal on behalf of the agency.
In 2018 the highest courts in countries across three continents have asserted that state intervention in the private life of their citizens who wish to (grow and) use cannabis is not always justified.
Under international laws, cultivation, supply and possession of cannabis should be allowed only for ‘medical and scientific purposes’. In general, possession of the drug for personal use should be a crime, to deter use, and most countries make this punishable by imprisonment. In recent years, however, several jurisdictions have reduced their penalties for cannabis users, and some have permitted supply of the drug, allowing us to observe different control models and their consequences.
This news item was published in the EMCDDA’s Cannabis drug policy news on 17.12.2018
In the US state of Colorado, use and sale of cannabis for recreational purposes has been legal since January 2014, and it has been commercialised for medical purposes since 2009. The main arguments for legalisation were that it would increase law enforcement efficiency, revenue and individual freedom.
The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces once again next summer to hold the eighth European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’ (1). Registration is now open for the two-week course, which will take place in the Portuguese capital from 24 June to 5 July (2). The initiative is also supported by the US National Institute on Drug Abuse (NIDA)(3).
This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context.
It explores the range of m-health applications available to users and professionals seeking information, support and advice in a wide range of EU languages.
The EMCDDA Management Board, meeting in Lisbon this week, held elections today for the positions of Chair and Vice-Chair of the Board.
The latest changes in Europe’s cocaine market are explored in a new report published today by the EU drugs agency (EMCDDA). The report follows an analysis in the European Drug Report 2018, which highlighted an increase in the availability of high-purity cocaine in Europe, shifting trafficking routes and rising numbers of first-time admissions to specialised treatment.
This publication is a user-friendly guide, taking the reader, step by step, through the trendspotter methodology developed by the EMCDDA to explore emerging drug trends, new patterns of use, developing drug markets and technologies. The trendspotter method involves the rapid collection and triangulation of data from a variety of sources, incorporating multiple social research methods, and drawing on rapid assessment and response methods.
Using trendspotter methodology, this report explores signs of increasing availability and consumption of cocaine in Europe, in an effort to increase our understanding of recent changes in the cocaine market. The study investigates the consequences of these developments on acute health harms linked to cocaine and crack use and reviews the current public health responses to problems related to these drugs.
This month, the EMCDDA approaches the end of its presidency of the EU Agencies’ Network on Scientific Advice (EU-ANSA) and looks back on a productive year (1).
Europe’s ability to rapidly respond to public health and social threats caused by new psychoactive substances (NPS/‘new drugs’) has been significantly strengthened thanks to new legislation applying from 23 November (1). The legislation strengthens the EU Early Warning System (EU EWS) and risk assessment procedures on NPS and shortens control processes.
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council conclusions of November 2013. The report gives also an overview of the purpose and aims of supply data collected by the EMCDDA.
What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in a new report published today by the EU drugs agency (EMCDDA): Medical use of cannabis and cannabinoids: questions and answers for policymaking.